49th ICAAC Annual Meeting: optimization of anti-infective use in the clinical setting

References

• Bronzwaer SL, Cars O, Buchholz U et al. A European study on the relationship between antimicrobial use and antimicrobial resistance. Emerg. Infect. Dis.8(3), 278–282 (2002).
   PubMed Web of Science ®Google Scholar
• Dellit TH, Owens RC, McGowan JE Jr et al. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin. Infect. Dis.44(2), 159–177 (2007).
   PubMed Web of Science ®Google Scholar
• Monnet DL, MacKenzie FM, Lopez-Lozano JM et al. Antimicrobial drug use and methicillin-resistant Staphylococcus aureus, Aberdeen, 1996–2000. Emerg. Infect. Dis.10(8), 1432–1441 (2004).
   PubMed Web of Science ®Google Scholar
• Arbo MD, Snydman DR. Influence of blood culture results on antibiotic choice in the treatment of bacteremia. Arch. Intern. Med.154(23), 2641–2645 (1994).
   PubMedGoogle Scholar
• Dunagan WC, Woodward RS, Medoff G et al. Antimicrobial misuse in patients with positive blood cultures. Am. J. Med.87(3), 253–259 (1989).
   PubMed Web of Science ®Google Scholar
• Gonzales R, Camargo CA Jr, MacKenzie T et al. Antibiotic treatment of acute respiratory infections in acute care settings. Acad. Emerg. Med.13(3), 288–294 (2006).
   PubMed Web of Science ®Google Scholar
• Gonzales R, Steiner JF, Sande MA. Antibiotic prescribing for adults with colds, upper respiratory tract infections, and bronchitis by ambulatory care physicians. JAMA278(11), 901–904 (1997).
   PubMed Web of Science ®Google Scholar
• Cheng VC, To KK, Li IW et al. Antimicrobial stewardship program directed at broad-spectrum intravenous antibiotics prescription in a tertiary hospital. Eur. J. Clin. Microbiol. Infect. Dis. (2009) (Epub ahead of print).
   PubMedGoogle Scholar
• Clinical Affairs Committee. Hospital pharmacists and infectious diseases specialists. Clin. Infect. Dis.27(1), 802 (1997).
   Google Scholar
• Drew RH, White R, MacDougall C, Hermsen ED, Owens RC Jr. Insights from the Society of Infectious Diseases Pharmacists on antimicrobial stewardship guidelines from the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America. Pharmacotherapy29(5), 593–607 (2009).
   PubMed Web of Science ®Google Scholar
• Paul M, Andreassen S, Tacconelli E et al. Improving empirical antibiotic treatment using TREAT, a computerized decision support system: cluster randomized trial. J. Antimicrob. Chemother.58(6), 1238–1245 (2006).
   PubMedGoogle Scholar
• Pestotnik SL, Classen DC, Evans RS, Burke JP. Implementing antibiotic practice guidelines through computer-assisted decision support: clinical and financial outcomes. Ann. Intern. Med.124(10), 884–890 (1996).
   PubMed Web of Science ®Google Scholar
• Rybak MJ, Lomaestro BM, Rotscahfer JC et al. Vancomycin therapeutic guidelines: a summary of consensus recommendations from the infectious diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists. Clin. Infect. Dis.49(3), 325–327 (2009).
   PubMed Web of Science ®Google Scholar
• Moise-Broder PA, Forrest A, Birmingham MC, Schentag JJ. Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections. Clin. Pharmacokinet.43(13), 925–942 (2004).
   PubMed Web of Science ®Google Scholar
• Sakoulas G, Moise-Broder PA, Schentag J, Forrest A, Moellering RC Jr, Eliopoulos GM. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J. Clin. Microbiol.42(6), 2398–2402 (2004).
   PubMed Web of Science ®Google Scholar
• Tenover FC, Moellering RC Jr. The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus. Clin. Infect. Dis.44(9), 1208–1215 (2007).
   PubMed Web of Science ®Google Scholar
• Lodise TP, Patel N, Lomaestro BM, Rodvold KA, Drusano GL. Relationship between initial vancomycin concentration–time profile and nephrotoxicity among hospitalized patients. Clin. Infect. Dis.49(4), 507–514 (2009).
   PubMed Web of Science ®Google Scholar
• Proctor RA. Role of folate antagonists in the treatment of methicillin-resistant Staphylococcus aureus infection. Clin. Infect. Dis.46(4), 584–593 (2008).
   PubMed Web of Science ®Google Scholar
• Trevino M, Martinez-Lamas L, Romero-Jung PA, Giraldez JM, Alvarez-Escudero J, Regueiro BJ. Endemic linezolid-resistant Staphylococcus epidermidis in a critical care unit. Eur. J. Clin. Microbiol. Infect. Dis.28(5), 527–533 (2009).
   PubMed Web of Science ®Google Scholar
• Fisher L, North D. Effectiveness of low-dose daptomycin in the treatment of vancomycin-resistant enterococcal urinary tract infections. Int. J. Antimicrob. Agents33(5), 493–494 (2009).
   PubMedGoogle Scholar
• Zhanel GG, Laing NM, Nichol KA et al. Antibiotic activity against urinary tract infection (UTI) isolates of vancomycin-resistant enterococci (VRE): results from the 2002 North American Vancomycin Resistant Enterococci Susceptibility Study (NAVRESS). J. Antimicrob. Chemother.52(3), 382–388 (2003).
   PubMed Web of Science ®Google Scholar
• Lin SJ, Schranz J, Teutsch SM. Aspergillosis case–fatality rate: systematic review of the literature. Clin. Infect. Dis.32(3), 358–366 (2001).
   PubMed Web of Science ®Google Scholar
• Gudlaugsson O, Gillespie S, Lee K et al. Attributable mortality of nosocomial candidemia, revisited. Clin. Infect. Dis.37(9), 1172–1177 (2003).
   PubMed Web of Science ®Google Scholar
• Andes DR, Ambrose PG, Hammel JP et al. Exposure–response (E–R) relationships for efficacy of micafungin in patients with invasive candidiasis (IC). Presented at: 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). San Francisco, CA, USA, 12–15 September 2009 (Abstract A1–424).
   Google Scholar
• Walsh T, Goutelle S, Jelliffe R et al. Intrapulmonary pharmacokinetics of micafungin in lung transplant patients. Presented at: 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). San Francisco, CA, USA, 12–15 September 2009 (Abstract A1–422).
   Google Scholar
• Crandon JL, Banevicius MA, Fang AF et al. Bronchopulmonary disposition of intravenous (IV) voriconazole (VRC) and anidulafungin (ANID) given in combination to healthy adults. Presented at: 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). San Francisco, CA, USA, 12–15 September 2009 (Abstract A1–423).
   Google Scholar
• Crandon JL, Banevicus MA, Fang AF et al. Bronchopulmonary disposition of intravenous voriconazole and anidulafungin given in combination to healthy adults. Antimicrob. Agents Chemother. (2009) (Epub ahead of print).
   Google Scholar
• Burkhardt O, Ellis S, Burhenne H et al. High caspofungin levels in alveolar cells of a lung transplant patient with suspected pulmonary aspergillosis. Int. J. Antimicrob. Agents34(5), 491–492 (2009).
   PubMedGoogle Scholar
• Katlama C, Haubrich R, Lalezari J et al. Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled trials. AIDS23(17), 2289–2300 (2009).
   PubMed Web of Science ®Google Scholar
• Steigbigel RT, Cooper DA, Kumar PN et al. Raltegravir with optimized background therapy for resistant HIV-1 infection. N. Engl. J. Med.359(4), 339–354 (2008).
   PubMed Web of Science ®Google Scholar
• Gulick RM, Lalezari J, Goodrich J et al. Maraviroc for previously treated patients with R5 HIV-1 infection. N. Engl. J. Med.359(14), 1429–1441 (2008).
   PubMed Web of Science ®Google Scholar
• Dumond JB, Yeh RF, Patterson KB et al. Antiretroviral drug exposure in the female genital tract: implications for oral pre- and post-exposure prophylaxis. AIDS21(14), 1899–1907 (2007).
   PubMed Web of Science ®Google Scholar
• Yeh RF, Rezk NL, Kashuba AD et al. Genital tract, cord blood, and amniotic fluid exposures of seven antiretroviral drugs during and after pregnancy in human immunodeficiency virus type 1-infected women. Antimicrob. Agents Chemother.53(6), 2367–2374 (2009).
   PubMedGoogle Scholar
• Lennox JL, DeJesus E, Lazzarin A et al. Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial. Lancet374(9692), 796–806 (2009).
   PubMed Web of Science ®Google Scholar
• Squires K, Olmscheid B, Zhang S. TDF-containing antiretroviral regimens in pregnancy: findings from the Antiretroviral Pregnancy Registry. Presented at: 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). San Francisco, CA, USA, 12–15 September 2009 (Abstract H-917).
   Google Scholar
• Nachman S, Samson P, Frenkel L et al. 24 week safety and efficacy from IMPAACT P1066: a Phase I/II, multicenter, open-label, noncomparative study to evaluate raltegravir in HIV-1 infected youth. Presented at: 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). San Francisco, CA, USA, 12–15 September 2009 (Abstract H-924a).
   Google Scholar
• Lalezari J, Sloan L, DeJesus E et al. Potent antiviral activity of S-GSK1349572, a next generation integrase inhibitor (INI), in INI-naive HIV-1-infected patients: ING111521 protocol. Presented at: 5th Conference on HIV Pathogenesis, Treatment, and Prevention (IAS). Cape Town, South Africa, 19–22 September 2009 (Abstract TUAB105).
   Google Scholar
• Lou Y, Min S, Chen S et al. Meta-analysis of safety for short-term dosing of an HIV integrase inhibitor, S/GSK1349572, from seven clinical studies. Presented at: 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). San Francisco, CA, USA, 12–15 September 2009 (Abstract H931).
   Google Scholar
• Min S, Song I, Borland J et al. Pharmacokinetics (PK) and safety in healthy subjects of S-GSK1349572, a next generation, once-daily HIV integrase inhibitor (INI). Presented at: 5th Conference on HIV Pathogenesis, Treatment, and Prevention (IAS). Cape Town, South Africa, 19–22 September 2009 (Abstract WEPEA099).
   Google Scholar
• Song I, Patel A, Min S et al. Evaluation of antacid and multivitamin (MVI) effects on S/GSK1349572 pharmacokinetics (PK) in healthy subjects. Presented at: 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). San Francisco, CA, USA, 12–15 September 2009 (Abstract A1–1303).
   Google Scholar